Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Bone Remodeling01:40

Bone Remodeling

39.9K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
39.9K
What is the Skeletal System?01:02

What is the Skeletal System?

56.0K
Overview
56.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.6K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma.

Hematology reports·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

Developing a Core Outcome Measurement Set for Adult ICU Patients, the CoreMS-ICU-A Protocol.

Acta anaesthesiologica Scandinavica·2026
Same author

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.

American journal of hematology·2026
Same author

Effectiveness of maintenance interventions promoting physical activity following exercise therapy for chronic conditions: an umbrella review.

British journal of sports medicine·2026
Same author

The impact of coccygectomy on sexual and social function in females with chronic coccygodynia: a cohort study investigation the impact of coccygectomy using patient reported outcome after one and two years.

BMC musculoskeletal disorders·2026

Related Experiment Video

Updated: Dec 13, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Multiple Myeloma Associated Bone Disease.

Stine Rasch1,2, Thomas Lund1,3, Jon Thor Asmussen4

  • 1Department of Haematology, Odense University Hospital, Kloevervaenget 10, 12th Floor, DK-5000 Odense, Denmark.

Cancers
|August 6, 2020
PubMed
Summary
This summary is machine-generated.

Multiple myeloma bone disease (MBD) impacts 80% of patients. Advances in diagnosis and treatment, including new imaging and therapies like denosumab, are improving patient outcomes and quality of life.

Keywords:
denosumabexerciseimagingmultiple myelomamyeloma bone diseaseosteolysispathophysiologyrehabilitationvertebral augmentationzoledronic acid

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.6K
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

86.7K

Related Experiment Videos

Last Updated: Dec 13, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.6K
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

86.7K

Area of Science:

  • Oncology
  • Hematology
  • Bone Metabolism

Background:

  • Lytic bone disease is a common complication of multiple myeloma (MM), significantly impacting patient morbidity and quality of life.
  • Myeloma-associated bone disease (MBD) presents a significant clinical challenge, necessitating advanced management strategies.
  • Recent progress has enhanced understanding of MBD pathophysiology, leading to improved diagnostic and therapeutic approaches.

Purpose of the Study:

  • To review key advancements in the understanding, diagnosis, and treatment of myeloma-associated bone disease (MBD).
  • To highlight the evolving landscape of MBD management in multiple myeloma patients.

Main Methods:

  • Literature review focusing on recent research in MBD pathophysiology, diagnostics, and therapeutics.
  • Analysis of current diagnostic standards, including low-dose whole-body CT, diffusion-weighted MRI, and PET/CT.
  • Evaluation of established and emerging treatment modalities, encompassing bisphosphonates, denosumab, radiotherapy, and supportive care.

Main Results:

  • Low-dose whole-body CT is recommended for MBD diagnosis over conventional skeletal surveys.
  • Advanced imaging like diffusion-weighted MRI and PET/CT are crucial for MBD assessment and monitoring.
  • Denosumab offers an alternative to bisphosphonates, particularly for patients with renal impairment.
  • Radiotherapy, cement augmentation, and cautious exercise programs are valuable in managing MBD complications.

Conclusions:

  • Significant progress has been made in diagnosing and treating myeloma-associated bone disease (MBD).
  • A multimodal approach integrating advanced imaging, pharmacotherapy, interventional procedures, and exercise is key to managing MBD.
  • Continued research and clinical application of these advancements promise to improve outcomes for multiple myeloma patients with bone disease.